Adagrasib, also known as MRTX849, is a potent, highly selective, oral available KRAS G12C inhibitor. MRTX849 maximizes inhibition by irreversibly locking the KRAS molecule in its inactive state, thereby preventing tumor cell growth which results in tumor cell death. MRTX849 exhibited significantly improved half-life and penetration into the tumor, shutting down KRAS signaling for the entire dosing interval, and showing a higher degree of antitumor activity than previous KRAS mutant-selective inhibitors.
Ras Inhibitors Related Products:
Lonafarnib; Kobe2602; Zoledronic acid; K-Ras-IN-1; Zoledronic acid hydrate; Kobe0065; Deltarasin; Salirasib; K-Ras(G12C) inhibitor